newsfilter
← Latest News
GlobeNewswire·

Tarsus to Participate in Upcoming Investor Conferences

  • Tarsus Pharmaceuticals management plans to attend the Guggenheim 3rd Annual Healthcare Conference on November 10, 2026, for a fireside chat at 12:30 p.m. PT.
  • The company will participate in the 2026 Jefferies Global Healthcare Conference on November 18 & 19, 2026.
  • Tarsus management is scheduled for a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026, at 11:30 a.m. PT.
  • Live webcasts, replays, & archived event information will be available on the Tarsus website.
  • XDEMVY is FDA-approved for treating Demodex blepharitis, while the company advances a pipeline including TP-04, TP-05, IRX-101, & gildeuretinol for ocular rosacea, Lyme disease prevention, ocular antiseptic use, & Stargardt disease respectively.
Company
Tarsus Pharmaceuticals, Inc
Keywords
Nasdaq:TARS, Tarsus Pharmaceuticals, Inc